{"nctId":"NCT02766608","briefTitle":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","startDateStruct":{"date":"2016-05-31","type":"ACTUAL"},"conditions":["Chronic Obstructive Pulmonary Disorder"],"count":2389,"armGroups":[{"label":"BFF MDI 320/9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: BFF MDI 320/9.6 μg"]},{"label":"BFF MDI 160/9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: BFF MDI 160/9.6 μg"]},{"label":"FF MDI 9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: FF MDI 9.6 μg"]},{"label":"BD MDI 320 μg","type":"EXPERIMENTAL","interventionNames":["Drug: BD MDI 320 μg"]},{"label":"Symbicort® TBH 400/12 μg","type":"OTHER","interventionNames":["Drug: Symbicort® TBH 400/12 μg BID"]}],"interventions":[{"name":"BFF MDI 320/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"name":"BFF MDI 160/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"name":"FF MDI 9.6 μg","otherNames":["Formoterol Fumarate Inhalation Aerosol"]},{"name":"BD MDI 320 μg","otherNames":["Budesonide Inhalation Aerosol"]},{"name":"Symbicort® TBH 400/12 μg BID","otherNames":["Symbicort® Turbuhaler"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Give their signed written informed consent to participate\n2. Are at least 40 years of age and no older than 80 years\n3. COPD patients who are symptomatic\n4. Must be receiving one or more inhaled bronchodilators as maintenance therapy\n\nExclusion Criteria:\n\n1. Current diagnosis of asthma,\n2. COPD due to α1-Antitrypsin Deficiency\n3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months\n4. Long-term-oxygen therapy (≥ 12 hours a day).","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)","description":"Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":null},{"groupId":"OG001","value":"0.017","spread":null},{"groupId":"OG002","value":"-0.003","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)","description":"Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.194","spread":null},{"groupId":"OG001","value":"0.179","spread":null},{"groupId":"OG002","value":"0.161","spread":null},{"groupId":"OG003","value":"0.022","spread":null},{"groupId":"OG004","value":"0.187","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).","description":"Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"5.5","spread":null},{"groupId":"OG003","value":"7.0","spread":null},{"groupId":"OG004","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"15.0","spread":null},{"groupId":"OG003","value":"14.9","spread":null},{"groupId":"OG004","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"20.5","spread":null},{"groupId":"OG003","value":"17.7","spread":null},{"groupId":"OG004","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24","description":"The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, \\& Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.12","spread":null},{"groupId":"OG001","value":"47.22","spread":null},{"groupId":"OG002","value":"41.59","spread":null},{"groupId":"OG003","value":"43.62","spread":null},{"groupId":"OG004","value":"53.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)","description":"Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":null},{"groupId":"OG001","value":"0.017","spread":null},{"groupId":"OG002","value":"-0.003","spread":null},{"groupId":"OG003","value":"-0.028","spread":null},{"groupId":"OG004","value":"0.039","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)","description":"Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.272","spread":null},{"groupId":"OG001","value":"0.258","spread":null},{"groupId":"OG002","value":"0.243","spread":null},{"groupId":"OG003","value":"0.116","spread":null},{"groupId":"OG004","value":"0.267","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)","description":"Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":null},{"groupId":"OG001","value":"-1.3","spread":null},{"groupId":"OG002","value":"-1.1","spread":null},{"groupId":"OG003","value":"-0.6","spread":null},{"groupId":"OG004","value":"-1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.157","spread":null},{"groupId":"OG001","value":"0.151","spread":null},{"groupId":"OG002","value":"0.160","spread":null},{"groupId":"OG003","value":"0.025","spread":null},{"groupId":"OG004","value":"0.131","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.190","spread":null},{"groupId":"OG001","value":"0.186","spread":null},{"groupId":"OG002","value":"0.201","spread":null},{"groupId":"OG003","value":"0.040","spread":null},{"groupId":"OG004","value":"0.167","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.207","spread":null},{"groupId":"OG001","value":"0.207","spread":null},{"groupId":"OG002","value":"0.215","spread":null},{"groupId":"OG003","value":"0.047","spread":null},{"groupId":"OG004","value":"0.190","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.225","spread":null},{"groupId":"OG001","value":"0.221","spread":null},{"groupId":"OG002","value":"0.236","spread":null},{"groupId":"OG003","value":"0.053","spread":null},{"groupId":"OG004","value":"0.211","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.253","spread":null},{"groupId":"OG001","value":"0.234","spread":null},{"groupId":"OG002","value":"0.244","spread":null},{"groupId":"OG003","value":"0.063","spread":null},{"groupId":"OG004","value":"0.221","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination","description":"Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.230","spread":null},{"groupId":"OG001","value":"0.215","spread":null},{"groupId":"OG002","value":"0.212","spread":null},{"groupId":"OG003","value":"0.073","spread":null},{"groupId":"OG004","value":"0.209","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Substudy: 12-hour PFT Endpoint FEV1 AUC0-12","description":"Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.135","spread":null},{"groupId":"OG001","value":"0.124","spread":null},{"groupId":"OG002","value":"0.117","spread":null},{"groupId":"OG003","value":"0.024","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":655},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Chronic obstructive pulmonary disease","Hypertension","Back pain"]}}}